Masako Mishima
Kawahara, 6068507, Japan
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 19 publications
MSH2 prevents liver tumorigenesis by regulating cell cycle checkpoints under chronic inflammation.
Journal: Carcinogenesis
Published: October 20, 2025
Lenvatinib Versus Atezolizumab Plus Bevacizumab as First-Line Treatment for Advanced Hepatocellular Carcinoma With a CRAFITY Score of 2: A Multi-Center Retrospective Study.
Journal: Hepatology research : the official journal of the Japan Society of Hepatology
Published: June 20, 2025
Acquisition Process and Clinical Relevance of dMMR-Associated Mutational Signatures in Hepatocellular Carcinoma.
Journal: Liver international : official journal of the International Association for the Study of the Liver
Published: November 17, 2024
Publisher Correction: CRAFITY score as a predictive marker for refractoriness to atezolizumab plus bevacizumab therapy in hepatocellular carcinoma: a multicenter retrospective study.
Journal: Journal of gastroenterology
Published: October 21, 2024
CRAFITY score as a predictive marker for refractoriness to atezolizumab plus bevacizumab therapy in hepatocellular carcinoma: a multicenter retrospective study.
Journal: Journal of gastroenterology
Published: June 05, 2024
TERT upregulation promotes cell proliferation via degradation of p21 and increases carcinogenic potential.
Journal: The Journal of pathology
Published: December 16, 2023
Mutational spectrum of hepatitis C virus in patients with chronic hepatitis C determined by single molecule real-time sequencing.
Journal: Scientific reports
Published: December 08, 2021
A simplified method to quantitatively predict the effect of lenvatinib on hepatocellular carcinoma using contrast-enhanced ultrasound with perfluorobutane microbubbles.
Journal: Quantitative imaging in medicine and surgery
Published: June 03, 2021
Mac-2 binding protein glycosylation isomer predicts tolerability and clinical outcome of lenvatinib therapy for hepatocellular carcinoma.
Journal: Journal of hepato-biliary-pancreatic sciences
Published: January 27, 2021
Branched-chain amino acid to tyrosine ratio is an essential pre-treatment factor for maintaining sufficient treatment intensity of lenvatinib in patients with hepatocellular carcinoma.
Journal: Journal of hepato-biliary-pancreatic sciences
Published: June 08, 2020
Last Updated: 09/26/2026